

PRESS INFORMATION



CytoTools

DermaTools, a CytoTools company, successfully extends current phase IIb study in Europe

- Internationalisation and inclusion of six further centres
- Treatment of first patients in Latvia and Lithuania planned for the end of August
- Extension of the study to safeguard the intended trial completion by the end of the year

Darmstadt, August 8, 2011 – DermaTools Biotech GmbH, a subsidiary of CytoTools AG, has extended the phase IIb study on the wound healing agent DermaPro® to six additional European centres in Latvia and Lithuania. Among other places, the study will be carried out at the renowned Pauls Stradins Clinical University Hospital in Riga – one of the leading health care centres in the Baltic region. This step is part of the process of gathering international experience with the active substance and preparing a European new drug registration. Additionally, this internationalisation is setting the course for a multinational phase III study.

Furthermore, with the application to the authorities of the two countries which has already been submitted, the intention is to accelerate the study. Therefore, the treatment of the first patients from the Baltic region is expected as soon as the end of August. Moreover, with this extension of the study, CytoTools AG intends to compensate for the development that the recruiting of patients at the German centres is taking longer than was originally planned. Consequently, the completion of the phase IIb study is expected for the end of the year.

This information contains certain forward-looking statements. These reflect the opinion of CytoTools at the date of this information release. The results which are actually achieved by CytoTools in the future may differ significantly from the statements made herein. CytoTools is not obliged to revise or update such forward-looking statements.

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: 52% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

PRESS INFORMATION



CytoTools

Contact:

CytoTools AG

Dr. Mark Andre Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: freyberg@cytotools.de

Press contact:

cometis

Janis Fischer

Unter den Eichen 7

D-65195 Wiesbaden

Tel.: +49-611-205855-64

Fax: +49-611-205855-66

E-Mail: fischer@cometis.de